Drug Abuse and Alcoholism Flashcards

A CMV driver presents for a DOT physical and discloses he completed an SAP (Substance Abuse Professional) return-to-duty program 18 months ago following a positive alcohol test. He has since undergone all required follow-up testing with no violations. However, his current employer's MRO records indicate one unexcused absence from a scheduled follow-up test 11 months ago that was ultimately rescheduled. How should the medical examiner proceed?

Answer: Certify the driver, as follow-up testing program compliance is the SAP's and employer's responsibility, not the medical examiner's

Under 49 CFR Part 391.41(b)(13) and FMCSA guidance, the medical examiner's role is to determine fitness at the time of examination. Follow-up testing program compliance and SAP oversight are the domain of the employer, SAP, and MRO — not the medical examiner. The ME should not adjudicate employer-level testing logistics; that falls outside the ME's certification authority. The driver's self-disclosure and documented return-to-duty completion are what the ME evaluates.

A driver applying for DOT certification has a documented history of alcohol use disorder (AUD) with last known heavy use 4 years ago. He presents a letter from his treating psychiatrist stating he is in 'sustained full remission' per DSM-5 criteria and has been stable on naltrexone 50mg daily for 2 years. What is the MOST accurate statement regarding this driver's eligibility?

Answer: The driver may be certified if the medical examiner determines the underlying condition is clinically stable and the medication does not impair safe driving ability

FMCSA does not maintain a blanket prohibited drug list for CMV certification beyond Schedule I substances and those impairing safe operation. Naltrexone is an opioid antagonist with no abuse potential and no CNS depression at therapeutic doses. The medical examiner must make an individualized determination: is the AUD in genuine sustained remission, and does the medication (naltrexone) impair the ability to safely operate a CMV? If both answers are favorable, certification is permissible. SAP evaluation is required only after a verified DOT program violation — not triggered merely by a history of AUD.

During a DOT physical, a driver admits to recreational marijuana use 'occasionally on weekends' but states he never drives within 24 hours of use. He presents a medical marijuana card from a state where it is legal. His urine drug screen, collected at the examination, returns negative for THC metabolites. What is the correct action?

Answer: Disqualify the driver because self-reported marijuana use, even recreational and off-duty, constitutes current use of a Schedule I substance under federal law

Under federal law (21 U.S.C. and FMCSA 49 CFR 391.41(b)(12)), marijuana remains a Schedule I controlled substance regardless of state law. A valid state medical marijuana card provides no federal exemption. FMCSA explicitly states that 'current use' includes any use of marijuana, and self-admitted use is disqualifying irrespective of a negative urine screen at the time of examination. A negative screen only reflects the testing window; it does not negate the driver's own disclosure of ongoing use.

A driver with a prior DUI conviction (8 years ago, single incident, no recurrence) is applying for DOT certification. He has been taking disulfiram (Antabuse) 250mg daily for 6 years as prescribed by his addiction medicine specialist. He denies any alcohol use and his clinical course is described as 'excellent.' What is the MOST defensible certification decision?

Answer: Certify the driver; disulfiram has no direct CNS-impairing effects and long-term use with no violations supports fitness

Disulfiram itself does not impair driving ability at therapeutic doses — it is not sedating and has no CNS-active mechanism in the absence of alcohol. FMCSA's concern is impairment of driving ability, not the pharmacological category of a prescribed medication. The driver's 6-year stable course, specialist follow-up, and absence of alcohol violations support a determination of fitness. While theoretical alcohol-exposure risks exist, the medical examiner assesses realistic operational risk — not remote pharmacological edge cases — and long-term disulfiram adherence without incident is clinically favorable.

An MRO reports to a medical examiner that a driver's DOT urine specimen was reported as a verified positive for opiates (morphine >2,000 ng/mL) but the driver produced a valid prescription for codeine. The MRO verified the result as negative after medical review. The driver's employer, however, submitted a separate reasonable suspicion referral citing witnessed erratic behavior on the day of collection. What is the medical examiner's correct approach?

Answer: Defer certification and evaluate the driver independently for clinical signs of opioid intoxication or impairment, treating the reasonable suspicion referral as a separate medical fitness concern

The MRO's verified negative resolves the drug test result under Part 40 — it legally becomes a negative test. However, the medical examiner's certification authority under Part 391 is independent of the drug testing program. Reasonable suspicion of impairment is a clinical fitness question, not a drug test result question. The ME must independently assess whether the driver currently meets the physical and mental standards for CMV operation. Erratic behavior on the day of the test is a clinical data point the ME must evaluate separately, potentially including examination for signs of substance-related impairment or other medical causes.

A 51-year-old driver is applying for certification and discloses a history of opioid use disorder treated with buprenorphine/naloxone (Suboxone) for 3 years under MOUD (medications for opioid use disorder). He is clinically stable, employed full-time outside of driving, and has no positive tests or relapses. His physician states he is in 'medically supported remission.' What does current FMCSA regulatory guidance state about this driver's eligibility?

Answer: The driver is categorically disqualified because buprenorphine is a Schedule III opioid and any scheduled opioid use disqualifies CMV operators under 49 CFR 391.41(b)(12)

As of the current FMCSA regulatory framework, drivers using methadone or buprenorphine for MOUD remain categorically disqualified from interstate CMV operation. FMCSA's 2022 MOUD guidance acknowledged the evolving landscape and called for further study, but did NOT change the disqualification standard — it directed an evidence review, not a policy change. The agency has not issued a final rule permitting MOUD drivers. Under 49 CFR 391.41(b)(12), a driver must not use any Schedule I substance or any amphetamine, narcotic, or habit-forming drug. Buprenorphine (Schedule III) falls under 'narcotic' in this context, and FMCSA has consistently maintained disqualification for MOUD patients pending rulemaking.